{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:03:39Z","timestamp":1777503819804,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11255-021-02975-8","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T14:02:27Z","timestamp":1628949747000},"page":"1085-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of acute and chronic nephrotoxicity in patients received cisplatin-based chemotherapy: has anything changed over time?"],"prefix":"10.1007","volume":"54","author":[{"given":"\u015eule \u00c7elik","family":"Kamac\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-9546","authenticated-orcid":false,"given":"G\u00fclay","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylia","family":"Ye\u015filova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eener","family":"Cihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"issue":"9","key":"2975_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00467-017-3765-6","volume":"33","author":"CD Barton","year":"2018","unstructured":"Barton CD, Pizer B, Jones C, Oni L, Pirmohamed M, Hawcutt DB (2018) Identifying cisplatin-induced kidney damage in paediatric oncology patients. Pediatr Nephrol 33(9):1467\u20131474","journal-title":"Pediatr Nephrol"},{"key":"2975_CR2","first-page":"47","volume":"1","author":"MH Hanigan","year":"2003","unstructured":"Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47\u201361","journal-title":"Cancer Ther"},{"issue":"2","key":"2975_CR3","first-page":"99","volume":"70","author":"K Almanric","year":"2017","unstructured":"Almanric K, Marceau N, Cantin A, Bertin \u00c9 (2017) Risk factors for nephrotoxicity associated with cisplatin. Can J Hosp Pharm 70(2):99\u2013106","journal-title":"Can J Hosp Pharm"},{"key":"2975_CR4","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","volume":"44","author":"L Bodnar","year":"2008","unstructured":"Bodnar L, Wcisle G, Gasowska-Bodnar A, Synowies A, Szarlec-Wcislo K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608\u20132614","journal-title":"Eur J Cancer"},{"key":"2975_CR5","unstructured":"US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE version) 4.0 (2020). https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE-4.03-JUNE"},{"key":"2975_CR6","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1248\/bpb.b16-00473","volume":"39","author":"T Miyoshi","year":"2016","unstructured":"Miyoshi T, Misumi N, Hiraike M, Mihara Y, Nishino T, Tsuruta M et al (2016) Risk factors associated with cisplatin-induced nephrotoxicity in patients with advanced lung cancer. Biol Pharm Bull 39:2009\u20132014","journal-title":"Biol Pharm Bull"},{"key":"2975_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","volume":"36","author":"SS Motwani","year":"2018","unstructured":"Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC (2018) Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol 36:682\u2013688","journal-title":"J Clin Oncol"},{"key":"2975_CR8","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.1684\/bdc.2012.1555","volume":"99","author":"A Lavole","year":"2012","unstructured":"Lavole A, Daniel S, Baudrin L, Gounant V, Ruppert AM, Epaud C et al (2012) Routine administration of a single dose of cisplatin \u2265 75 mg\/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer 99:E43-348","journal-title":"Bull Cancer"},{"key":"2975_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.08070715","volume":"11","author":"S Latcha","year":"2016","unstructured":"Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11:1173\u20131179","journal-title":"Clin J Am Soc Nephrol"},{"key":"2975_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","volume":"88","author":"FE De Jongh","year":"2003","unstructured":"De Jongh FE, Van Veen RN, Veltman SJ, De Wit R, Van der Burg ME, Van den Bent MJ et al (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88:1199\u20131206","journal-title":"Br J Cancer"},{"key":"2975_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/COC.0000000000000301","volume":"41","author":"J Faig","year":"2018","unstructured":"Faig J, Haughton M, Taylor RC, D\u2019Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA et al (2018) Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol 41:432\u2013440","journal-title":"Am J Clin Oncol"},{"key":"2975_CR12","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2001.19.17.3733","volume":"19","author":"FE De Jongh","year":"2001","unstructured":"De Jongh FE, Verweij J, Loos WJ, De Wit R, De Jonge MJ, Planting AS et al (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733\u20133739","journal-title":"J Clin Oncol"},{"key":"2975_CR13","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10061","volume":"2","author":"VA Luyckx","year":"2011","unstructured":"Luyckx VA, Shukha K, Brenner BM (2011) Low nephron number and its clinical consequences. Rambam Maimonides Med J 2:e0061","journal-title":"Rambam Maimonides Med J"},{"key":"2975_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2147\/TCRM.S165531","volume":"14","author":"JQ Liu","year":"2018","unstructured":"Liu JQ, Cai GY, Wang SY, Song YH, Xia YY, Liang S et al (2018) The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly. Ther Clin Risk Manag 14:1279\u20131285","journal-title":"Ther Clin Risk Manag"},{"key":"2975_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11357-015-9844-3","volume":"37","author":"J Wen","year":"2015","unstructured":"Wen J, Zeng M, Shu Y, Guo D, Sun Y, Guo Z et al (2015) Aging increases the susceptibility of cisplatin-induced nephrotoxicity. Age (Dordr) 37:112","journal-title":"Age (Dordr)"},{"key":"2975_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cger.2013.05.001","volume":"29","author":"MH Rosner","year":"2013","unstructured":"Rosner MH (2013) Acute kidney injury in the elderly. Clin Geriatr Med 29:565\u2013578","journal-title":"Clin Geriatr Med"},{"key":"2975_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J (2011) The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50:99\u2013110","journal-title":"Clin Pharmacokinet"},{"key":"2975_CR18","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1186\/s12885-019-6233-9","volume":"19","author":"MJDL van der Vorst","year":"2019","unstructured":"van der Vorst MJDL, Neefjes ECW, Toffoli EC, Oosterling-Jansen JEW, Vergeer MR, Leemans CR et al (2019) Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer 19:1066","journal-title":"BMC Cancer"},{"key":"2975_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1159\/000356587","volume":"85","author":"T Mizuno","year":"2013","unstructured":"Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y et al (2013) The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85:364\u2013369","journal-title":"Oncology"},{"key":"2975_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142225","volume":"10","author":"ZY Bhat","year":"2015","unstructured":"Bhat ZY, Cadnapaphornchai P, Ginsburg K, Sivagnanam M, Chopra S, Treadway CK et al (2015) Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS ONE 10:e0142225","journal-title":"PLoS ONE"},{"key":"2975_CR21","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.2215\/CJN.01120211","volume":"6","author":"CV Thakar","year":"2011","unstructured":"Thakar CV, Christianson A, Himmelfarb J, Leonard AC (2011) Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 6:2567\u20132572","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02975-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:25:57Z","timestamp":1649784357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02975-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2975"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02975-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}